Bone cancer organoids for drug discovery
2022
University of California, Los Angeles, USA
In this proof-of-concept study, organoids from seven chordoma tumour samples obtained from five patients presenting with tumours in different sites and stages of the rare disease were established. The organoids recapitulated features of the original parent tumours and inter-as well as intrapatient heterogeneity between samples obtained from the same patient at different time points and sites. High-throughput screenings of > 230 drugs were performed and the most effective molecules for the treatment of the respective tumour were identified. The high-throughput screening platform allows testing of hundreds of therapeutic agents, with results available within a week from surgery. It may be used to tailor therapy to each individual patient.
Personalized chordoma organoids for drug discovery studies
Alice Soragni
Added on: 03-25-2022
[1] https://www.science.org/doi/10.1126/sciadv.abl3674
